Trump administration drops plan to impose tariffs on Indian generic drugs

“The Trump administration has shelved plans to impose tariffs on Indian generic drugs, providing a major relief to the Indian pharmaceutical industry and American patients. This decision averts the risk of rising drug prices and shortages in the US, as cheaper medicines from India save the US healthcare system billions of dollars”

New Delhi 10/10/2025 Report by Santosh Seth

Major news from Washington has brought relief to both the Indian pharmaceutical industry and American patients. The Trump administration has temporarily shelved plans to impose tariffs on Indian generic drugs, bringing a sigh of relief to major Indian pharmaceutical companies Cipla, Sun Pharma, and Dr. Reddy’s Laboratories.

In fact, nearly half of the generic drugs used in the US come from India, and imposing tariffs on them could increase drug prices and directly impact the pockets of ordinary Americans.

Some Trump administration advisors believed that drug manufacturing should be brought back to the US under the “Make in America” ​​policy, while many economic experts warned that doing so could lead to skyrocketing drug prices and a shortage in the market.

For now, the government has wisely limited the scope of the investigation and shelved the idea of ​​tariffs on low-cost drugs from India.

Statistics show that in 2022 alone, Indian medicines saved the US healthcare system approximately $219 billion. Furthermore, over the past decade, Indian generic medicines have saved the US more than $1.3 trillion.

India is not called the “Pharmacy of the World” for nothing. Most medicines for blood pressure, depression, cholesterol, diabetes, and stomach ailments in the US come from Indian companies.

Following this government decision, one thing is clear: India’s pharmaceutical industry is not only protecting the world’s health but also saving American pockets. For now, American patients will continue to benefit from this Indian formula of “lower prices, better treatment.”